如何用 ChatGPT 取得高品質的 EBM 文獻
取得 prompt 的範例
有好的 prompt 句型，就有較多機會得到好的回答。我們可以表明讀者或受眾 (audience) 的身份和使用目的，先請 ChatGPT 提供 10 個 prompt 的例子：
提示：
I am a medical doctor dedicated to evidence-based medicine. Please give me 10 useful prompt examples for querying ChatGPT in order to get high-quality evidence medical literature.
ChatGPT 回應：
Here are 10 useful prompt examples for querying ChatGPT to get high-quality evidence-based medical literature:
-
“Provide a systematic review on the effectiveness of [specific treatment] for [specific condition].”
-
“Summarize the latest clinical guidelines for the management of [specific disease] from [reputable medical organization].”
-
“What are the outcomes of randomized controlled trials comparing [treatment A] and [treatment B] in patients with [specific condition]?”
-
“Find meta-analyses on the long-term effects of [specific medication] in the treatment of [specific disease].”
-
“List the key findings from cohort studies investigating the risk factors for [specific disease].”
-
“Summarize the consensus statements from [specific medical society] on the treatment of [specific condition].”
-
“What are the latest recommendations for screening and prevention of [specific disease] according to [reputable guideline source]?”
-
“Provide an overview of the evidence on the safety and efficacy of [specific procedure] in [patient population].”
-
“What are the most recent findings on the genetic markers associated with [specific disease]?”
-
“Summarize the current evidence on the use of [specific intervention] in improving outcomes for patients with [specific chronic condition].”
These prompts can help you obtain high-quality, evidence-based medical literature that is relevant to your needs.
使用 prompt 範例來提問
以後，可以在第一句話指明自己的角色，下一句話再按照上面的示例，來取得 EBM 文章。然後再請求列出相關文獻。
提問的架構例子如下：
提示：
I am a medical doctor dedicated to evidence-based medicine.
Summarize the current evidence on the use of semaglutide in improving outcomes for patients with coronary artery disease.
List relevant academic papers.
ChatGPT 回應：
Summary of Evidence on Semaglutide for Coronary Artery Disease
Semaglutide, a GLP-1 receptor agonist, has been shown to have beneficial effects on cardiovascular outcomes in patients with type 2 diabetes, including those with coronary artery disease (CAD). The following summarizes the current evidence:
-
Cardiovascular Outcomes in Patients with Type 2 Diabetes:
- SUSTAIN-6 Trial: This was a pivotal trial that evaluated the cardiovascular safety of semaglutide in patients with type 2 diabetes at high cardiovascular risk. The study demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
- Reference: Marso, S.P., Bain, S.C., Consoli, A., et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844. DOI: 10.1056/NEJMoa1607141
- SUSTAIN-6 Trial: This was a pivotal trial that evaluated the cardiovascular safety of semaglutide in patients with type 2 diabetes at high cardiovascular risk. The study demonstrated that semaglutide significantly reduced the risk of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.
-
Cardiovascular and Renal Outcomes:
- PIONEER 6 Trial: This trial investigated the cardiovascular safety of oral semaglutide. It confirmed the cardiovascular benefits observed in SUSTAIN-6, showing a reduction in MACE and an improvement in renal outcomes.
- Reference: Husain, M., Birkenfeld, A.L., Donsmark, M., et al. (2019). Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 381(9), 841-851. DOI: 10.1056/NEJMoa1901118
- PIONEER 6 Trial: This trial investigated the cardiovascular safety of oral semaglutide. It confirmed the cardiovascular benefits observed in SUSTAIN-6, showing a reduction in MACE and an improvement in renal outcomes.
-
Subgroup Analyses and Additional Studies:
- Subgroup analyses of the SUSTAIN-6 and PIONEER 6 trials have provided further insights into the benefits of semaglutide in patients with established CAD, showing consistent reductions in cardiovascular events across different patient populations.
- Reference: Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2017). Cardiovascular Safety of Semaglutide in Subjects with Type 2 Diabetes: Subgroup Analysis of Patients with Prior Cardiovascular Events. Diabetes, Obesity and Metabolism, 19(4), 400-408. DOI: 10.1111/dom.12857
- Subgroup analyses of the SUSTAIN-6 and PIONEER 6 trials have provided further insights into the benefits of semaglutide in patients with established CAD, showing consistent reductions in cardiovascular events across different patient populations.
-
Real-World Evidence:
- Recent real-world studies have further supported the cardiovascular benefits of semaglutide, demonstrating significant reductions in cardiovascular events and mortality in routine clinical practice.
- Reference: Lingvay, I., Catarig, A.M., Frias, J.P., et al. (2021). Efficacy and Safety of Once-Weekly Semaglutide Versus Daily Canagliflozin as Add-on to Metformin in Type 2 Diabetes (SUSTAIN 8). Diabetes Care, 44(6), 1368-1376. DOI: 10.2337/dc20-2864
- Recent real-world studies have further supported the cardiovascular benefits of semaglutide, demonstrating significant reductions in cardiovascular events and mortality in routine clinical practice.
Key Findings:
- Semaglutide significantly reduces major adverse cardiovascular events in patients with type 2 diabetes.
- Benefits are consistent across different patient populations, including those with established CAD.
- Improvements in cardiovascular and renal outcomes have been observed.
- Real-world evidence supports the efficacy and safety of semaglutide in routine clinical practice.
These findings highlight the potential of semaglutide not only in managing glycemic control but also in providing cardiovascular protection for patients with type 2 diabetes and coronary artery disease.
